European Primary Care Cardiovascular Society

The 2021 Polish guidelines on diagnosis and therapy of lipid disorders

5' education - Dec. 7, 2021 - Prof. Maciej Banach, MD, PhD

An algorithm-based program for cardiovascular healthcare

3' education - Nov. 22, 2021 - Alexander J. Blood, MD

Does low-dose aspirin lower risk of dementia in T2DM?

3' education - Nov. 16, 2021 - Prof. Jane Armitage

Assessing the effect of individual triggers for AF

3' education - Nov. 15, 2021 - Prof. Gregory Marcus, MD

Effects of coffee consumption on acute physiological changes: A randomized trial

3' education - Nov. 14, 2021 - Prof. Gregory Marcus, MD

Use of non-physician providers to control BP: An ambitious project

3' education - Nov. 14, 2021 - Prof. Keith Ferdinand, MD

Effective lowering of CV events by non-steroidal MRA in patients with diabetes and CKD

5' education - Oct. 5, 2021 - Prof. Bertram Pitt, MD

A pooled analysis of two large HF trials with SGLT2i shows exciting findings

3' education - Oct. 5, 2021 - Milton Packer, MD

Benefit of SGLT2i in HFpEF by reduction of clinically meaningful CV events

3' education - Sep. 15, 2021 - Prof. Stefan Anker, MD, PhD

Reduction of stroke, CV events and death when switching to a salt substitute

5' education - Sep. 12, 2021 - Prof. Bruce Neal, MD, PhD

The 2021 ESC HF guidelines: What is new regarding patients with EF>40%?

3' education - Sep. 10, 2021 - Prof. Carolyn Lam, MD, PhD

After stopping therapy, continued benefit of statin treatment

5' education - July 12, 2021 - Jackie Bosch, PhD

IL-6 inhibition in CKD for CV risk reduction

5' education - June 1, 2021 - Prof. Paul Ridker, MD
Experts in dialogue - LDL-c goal attainment in high risk patients

Statin-intolerant patients and lipid-lowering therapies

15' education - June 1, 2021 - Prof. Maciej Banach, MD, PhD and prof. Ulrich Laufs, MD, PhD
Experts in dialogue - LDL-c goal attainment in high risk patients

Current barriers and challenges in achieving LDL-c goals

15' education - June 1, 2021 - Prof. Lale Tokgözoğlu, MD and prof. Kausik Ray, MD - Online CME

Controversy on omega-3FAs trials

5' education - May 27, 2021 - Prof. Eileen Handberg, PhD

Proven safety with ARNI in MI patients, but no definite difference for primary endpoint

5' education - May 27, 2021 - Prof. Marc Pfeffer, MD, PhD

Clinical outcomes not different with 81 mg vs. 325 mg aspirin in established CVD

5' education - May 26, 2021 - William Schuyler Jones, MD
Experts in dialogue - LDL-c goal attainment in high risk patients

How are we doing: The gap between guideline LDL-c goals and current practice

15' education - May 11, 2021 - Prof. François Mach, MD and prof. Erik Stroes, MD, PhD
Experts in dialogue - LDL-c goal attainment in high risk patients

Benefit of LDL-c lowering: a proven case

15' education - May 4, 2021 - Prof. Kausik Ray, MD and prof. John Kastelein, MD, PhD

Online self-assessment for nonprescription statin therapy

Literature - Jan. 4, 2022 - Nissen SE et al. - J Am Coll Cardiol. 2021

A study compared the concordance between participant and clinician assessment of eligibility for rosuvastatin 5 mg using an at-home web-based application.

Association of sodium and potassium intakes with CV risk

Literature - Jan. 4, 2022 - Ma Y, et al. - N Engl J Med. 2021
In a pooled analysis of six cohort studies, higher sodium and lower potassium intakes measured by multiple 24-h urine samples were associated with higher CV risk in a dose-response manner.

In a pooled analysis of six cohort studies, higher sodium and lower potassium intakes measured by multiple 24-h urine samples were associated with higher CV risk in a dose-response manner.

Functional iron deficiency linked with incident CHD and mortality in the general population

Literature - Dec. 20, 2021 - Schrage B et al. - ESC Heart Fail. 2021

Functional iron deficiency is a relevant risk factor for CVD and mortality in the general population according to the authors of a study that investigated the relationship between iron deficiency and incident CVD and mortality.

Cumulative LDL-c exposure linked with future CHD risk

Literature - Dec. 14, 2021 - Zhang Y, et al. - JAMA Cardiol. 2021

Cumulative LDL-c and time-weighted average LDL-c during young adulthood and middle age (18-60 years) are associated with risk of incident CHD, independent of midlife LDL-c, in a cohort study of 18,288 participants.

Cost-effectiveness of a population genomic screening strategy for familial hypercholesterolemia

Literature - Dec. 14, 2021 - Marquina C et al. - Eur Heart J. 2021

A cost-effectiveness study suggests that population genomic screening for FH in young adults could be cost-effective from a healthcare perspective and cost-saving from a societal perspective at testing costs that are feasible.

The 2021 Polish guidelines on diagnosis and therapy of lipid disorders

5' education - Dec. 7, 2021 - Prof. Maciej Banach, MD, PhD
Watch a video by prof. Banach, who gives an overview of the key messages in the new Polish lipid guidelines.

Watch a video by prof. Banach, who gives an overview of the key messages in the new Polish lipid guidelines.

ESC Guidance document on diagnosis and treatment of CVD during the COVID-19 pandemic

News - Dec. 6, 2021

The Task Force for the management of COVID-19 of the ESC has published two documents that are aimed to provide guidance for the diagnosis and management of CVD during the COVID-19 pandemic.

An algorithm-based program for cardiovascular healthcare

3' education - Nov. 22, 2021 - Alexander J. Blood, MD
Alexander Blood talks about the design of a remote algorithm-based program for hypertension and lipid management and shares the outcomes of the first 10,000 patients enrolled in this program.

AHA 2021 Alexander Blood talks about the design of a remote algorithm-based program for hypertension and lipid management and shares the outcomes of the first 10,000 patients enrolled in this program.

Remote program for improvement of lipid and hypertension management

News - Nov. 22, 2021

AHA 2021 This remote hypertension and LDL-c management program enrolled over 10,000 patients at high CV risk. The program effectively improved hypertension and LDL-c control across a diverse health care network.

SGLT2i reduces composite of CV death or HF hospitalization in patients with HF and LVEF ≥50%

News - Nov. 17, 2021

AHA 2021 This analysis of the EMPEROR-Preserved trail showed that empagliflozin reduced the primary endpoint of time to first event of CV death or HF hospitalization by 17%, compared to placebo, in HF patients with LVEF ≥50%.

Does low-dose aspirin lower risk of dementia in T2DM?

3' education - Nov. 16, 2021 - Prof. Jane Armitage
 It is not clear yet what the effect of aspirin is on the risk of dementia in patients with T2DM. Prof. Armitage presents a study in which this was investigated using data of the ASCEND trial.

AHA 2021 It is not clear yet what the effect of aspirin is on the risk of dementia in patients with T2DM. Prof. Armitage presents a study in which this was investigated using data of the ASCEND trial.

No significant effect of aspirin on dementia outcomes in patients with T2DM

News - Nov. 16, 2021

AHA 2021 Using data of the ASCEND trial, this study showed that there was no significant effect of aspirin on dementia outcomes compared to placebo in patients with T2DM.

Agenda